GLP-1 agonists have the potential to become some of the best selling drugs of all time Targeting very large and rapidly growing markets Potential differentiation in dual-acting mechanism, biased signaling, and oral delivery GLP-1/GIP dual agonists have demonstrated greater weight loss than GLP-1 mono-agonists Positive early clinical data Weight loss observed in early clinical trials of CT-388 appears to be lower than that of approved GLP-1 and GLP-1/GIP agonists Will need to demonstrate some level of clinical differentiation, or comparable clinical activity and lower cost, to garner significant revenue Late-stage trials in Type 2 Diabetes and obesity are very expensive Drugs will need to generate billions in annual sales to justify price paid Carmot Therapeutics was acquired by Roche for $2.7 billion in December 2023
StatPearls Publishing, Treasure Island (FL) Wu Y-H, Tseng C-P, Cheng M-L et al (2008) Glucose-6-phosphate dehydrogenase deficiency enhances human coronavirus 229E infection
Providers typically follow established titration schedules to allow tolerance to develop
For glycemic control in type 2 diabetes, treatment is typically continued indefinitely as long as it remains effective and well-tolerated, with periodic assessment of the ongoing need for therapy
"availability is subject to change") These are brand-stated "starting at" prices - the actual cost may vary based on dosage, titration level, and program tier
